Deep Genomics
- Founded: 2014
- Location: Toronto, ON
- Employee range: 50 - 200
- Clinical stage: RD
- Therapy area: CNS conditions
- Drug types: NEU, GEN
- Lead product: Undisclosed
- Product link: https://www.deepgenomics.com/pipeline/
- Funding: $40M B Jan 2020
- Investors: Future Ventures, Amplitude Ventures, Magnetic Ventures, Khosla Ventures, True Ventures
deepgenomics.com linkedin.com job board
Short description:
AI-discovery, Oligonucleotide Therapies
Drug notes:
Additional undisclosed programs RD CNS conditions, metabolic conditions, undisclosed
Long description:
Deep Genomics is using AI to build life-saving genetic therapeutics. Biology is too complex for the human mind to comprehend, so future drug development will depend on AI assistance. By using the revolutions in AI, RNA biology and automation, Deep Genomics is designing RNA therapies for any gene and any genetic condition. Deep Genomics’ proprietary AI Workbench identifies novel targets from evaluating thousands of possibilities to identify the best therapeutic candidates. Lead candidates have been identified for over 50% of the novel targets Deep Genomics has tested so far. Now, Deep Genomics is creating AI Workbench 3.0 to expand the number of mechanisms and genetic variants analyzed, so the company can tackle complex genetic diseases.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com